PT-141 (Bremelanotide) vs MOTS-c Side-Effect Profile: Head-to-Head Comparison

HealthRX.com

Bremelanotide side effects are measured; MOTS-c has no human data

Print or save as PDF

Key numbers

  • 40.0%Nausea rate in women given bremelanotide in the phase 3 trials, the most common side effectSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 8%Share of treated women who stopped the trials because of nausea, the leading reason for stoppingSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 6 mmHgMaximal systolic blood pressure rise after a bremelanotide dose (diastolic maximum is 3 mmHg)Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 1.75 mgDose of one bremelanotide (Vyleesi) autoinjector, used as needed by premenopausal womenSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • PT-141 status / FDA-approved as Vyleesi (June 21, 2019) for acquired, generalized HSDD in premenopausal women [1][3]
  • MOTS-c status / Not an FDA-approved drug; no approved product exists [2]
  • PT-141 safety database / 627 women on drug in the pooled phase 3 trials [1]
  • Most common PT-141 effect / Nausea, 40.0% vs 1.3% on placebo [1]
  • Stopped for side effects / 18% on PT-141 vs 2% on placebo [1]
  • MOTS-c human dosing / No approved dose; nominated products were 5 mg and 10 mg subcutaneous injections [2]
  • MOTS-c stated concern / Immunogenicity risk from peptide aggregation and impurities [2]
  • Sport status / MOTS-c prohibited at all times (WADA S4.4.1); bremelanotide is not named on the 2026 or 2027 Lists [4][5]

The short answer

PT-141 is bremelanotide, approved by FDA as Vyleesi (NDA 210557) on June 21, 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is a 1.75 mg subcutaneous autoinjector used as needed at least 45 minutes before sexual activity. The label says no more than one dose in 24 hours and that more than 8 doses a month is not recommended [1][3]. MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, first reported in 2015, and it is not an FDA-approved drug or a component of one [2][6].

The two are not measured the same way. Bremelanotide has a prescribing information document with an adverse-reactions section built on two identical phase 3 trials in 1,247 premenopausal women [1][7]. MOTS-c's information comes from cells, mice and regulators.

PT-141: the side effects with numbers

In the pooled phase 3 program (RECONNECT, 1,247 women; 627 received bremelanotide, 620 placebo), the label lists these reactions at 2% or more and above placebo, bremelanotide vs placebo: nausea 40.0% vs 1.3%; flushing 20.3% vs 0.3%; injection-site reactions 13.2% vs 8.4%; headache 11.3% vs 1.9%; vomiting 4.8% vs 0.2%; cough 3.3% vs 1.3%; fatigue 3.2% vs 0.5%; hot flush 2.7% vs 0.2%; paresthesia 2.6% vs 0%; dizziness 2.2% vs 0.5%; nasal congestion 2.1% vs 0.5% [1].

Serious adverse reactions were reported in 1.1% of women on bremelanotide and 0.5% on placebo. Eighteen percent of treated women stopped the trials because of an adverse reaction, against 2% on placebo; the leading reasons were nausea 8%, headache 2%, vomiting 1%, flushing 1% and injection-site reactions 1% [1].

Nausea

Nausea is the dominant effect. Median onset was within one hour of the dose and it lasted about two hours. It was most common after the first dose (21% of patients) and fell to about 3% with later doses. Thirteen percent of treated women received an anti-emetic and 8% stopped the trials because of nausea [1].

In a phase 4 single-dose study, 228 healthy women were randomized to 8 mg oral ondansetron or placebo 30 minutes before a 1.75 mg dose. There was no significant difference in nausea, and the label says pretreatment with oral ondansetron is not recommended [1].

Blood pressure and heart rate

The label's 6 mmHg systolic and 3 mmHg diastolic figures are maximal increases, not averages. They peaked 2 to 4 hours after a dose, came with a heart-rate reduction of up to 5 beats per minute, and usually resolved within 12 hours [1]. In a separate open-label ambulatory monitoring study of 127 premenopausal women dosed once daily for 8 days, the mean daytime increase was 1.9 mmHg systolic (95% CI 1.0 to 2.7) and 1.7 mmHg diastolic (95% CI 0.9 to 2.4), with a mean heart-rate decrease of 0.5 beats per minute [1].

Bremelanotide is contraindicated in uncontrolled hypertension or known cardiovascular disease and is not recommended for people at high risk of cardiovascular disease. The label says to consider cardiovascular risk and confirm blood pressure is well controlled before starting and periodically during treatment [1].

Hyperpigmentation

Focal hyperpigmentation (face, gums and breasts) was reported by 1% of women receiving up to 8 doses a month in the phase 3 trials, and by no one on placebo. With daily dosing the rate is far higher: in another study 38% developed it after 8 consecutive days, and a further 14% after 8 more days [1]. People with dark skin were more likely to develop it, and resolution was not confirmed in all patients after stopping. The label says to consider discontinuing if hyperpigmentation develops [1].

Injection sites and the rest

Injection-site reactions (13.2%) include pain, erythema, hematoma, pruritus, bruising and paresthesia [1]. In the 52-week open-label extension, in which 684 women received bremelanotide with no placebo arm, the most common drug-related events were nausea 40.4%, flushing 20.6% and headache 12.0% [8]. In the trials most women used the drug two to three times a month and no more than once a week [1].

A single case of acute hepatitis (transaminases more than 40 times the upper limit of normal) occurred in the open-label extension after 10 doses. Another cause was not identified, so a role for Vyleesi could not be excluded [1].

What people on Reddit report

Forum accounts from people who have used bremelanotide themselves. They describe nausea, skin darkening and how long effects lasted, and their experiences differ widely.

CatsAndWings · NTNPerformance

nausea is only a problem for first 2-3 times you use it.

Reports that nausea was a problem only during the first few uses, and that skin pigmentation was very noticeable.

Read the source discussion

ReadingRedditAllDay · NTNPerformance

I have to take it before bed so I can sleep through the nausea. Still have same food results the following day.

Takes it at bedtime to sleep through the nausea and reports the same food results the following day.

Read the source discussion

Aggravating-Grade297 · NTNPerformance

Orgasms are definitely stronger. No nausea at that low dose at all.

Reports no nausea at a very low dose and stronger orgasms.

Read the source discussion

Questions worth asking

Choose the questions you want to keep

MOTS-c: what its safety record contains

FDA reviewed MOTS-c in July 2026 and found no clinical study of it given to a human by any route; the 12 papers the nominator cited were not clinical studies, and no animal toxicity studies were identified [2]. No MOTS-c adverse-event reports were retrieved in FDA's search through March 9, 2025 [2].

What FDA did state as a concern is immunogenicity. Injected peptides can aggregate and carry peptide-related impurities, and no immunogenicity data exist for this 16-amino-acid peptide [2]. MOTS-c sits in the 'nominated but withdrawn' table on FDA's page of bulk substances that may present significant safety risks. Removal from the higher-risk category was not a finding that it is safe [9]. An in-vitro study FDA cites found MOTS-c is rapidly broken down in human blood, which raises the question of whether injecting it can produce active levels in people [2].

The animal work is about metabolism and performance rather than safety. In mice, 0.5 mg/kg/day intraperitoneally for 8 weeks produced about 20% lower body weight on a high-fat diet, and in one study a late-life schedule of 15 mg/kg three times weekly from 23.5 months of age lengthened median lifespan from 912 to 970 days [2][6][10]. FDA noted that the molecular targets are unknown and no dose-response relationships were assessed, and rodent mg/kg doses cannot be converted into human doses [2]. The products nominated for human use were 5 mg and 10 mg subcutaneous injections; there is no approved dose [2].

Regulatory and sport status

Bremelanotide is not named on WADA's 2026 or 2027 Prohibited Lists [4][5]. MOTS-c is named in WADA class S4.4.1 (activators of AMP-activated protein kinase) and is prohibited at all times, in and out of competition [4][5].

Vyleesi is the FDA-approved bremelanotide product, now held by Cosette Pharmaceuticals. 'PT-141' sold as a compounded or research-use peptide is not Vyleesi and is not an FDA-approved drug; compounded drugs are not reviewed by FDA for safety, effectiveness or quality before marketing [1][11]. Bremelanotide does not appear on FDA's list of bulk substances that may present significant safety risks when compounded, and it is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [9][12][13].

MOTS-c is named in that HHS draft policy, which covers the acetate form given by subcutaneous or intramuscular injection. The notice says it does not establish any rights for any person and is not binding, and it is neither an approval nor a listing [11][13]. FDA's Pharmacy Compounding Advisory Committee voted on July 23, 2026 in favor of adding MOTS-c to the compounding bulks list, against FDA staff's recommendation; the vote is advice only and MOTS-c is not on the list [14][2].

Interactions and pregnancy in the Vyleesi label

The label says to avoid Vyleesi with oral naltrexone-containing products used for alcohol or opioid addiction, because bremelanotide may significantly decrease naltrexone exposure. It also says to avoid it with oral drugs that depend on threshold blood concentrations, such as antibiotics, because it may slow gastric emptying [1]. For pregnancy, the label says to discontinue Vyleesi if pregnancy is suspected and to use effective contraception; in dogs, fetal harm occurred at exposures at least 16 times the human exposure [1]. FDA approved a labeling supplement on October 22, 2026 that updates the pregnancy section [15].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. According to the trial summary, what share of women treated with Vyleesi had nausea?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Which peptide has the worse side-effect profile?
There is no basis for ranking them. PT-141 has measured rates from 627 treated women, including nausea in 40.0%, flushing in 20.3% and discontinuation for adverse reactions in 18%, while MOTS-c has no human rates to compare against [1][2].
How much does PT-141 raise blood pressure?
The maximal increase in clinical studies was 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after a dose and usually returning to baseline within 12 hours. In a separate 8-day ambulatory study of 127 women, the mean daytime rise was 1.9 mmHg systolic and 1.7 mmHg diastolic [1].
Does ondansetron prevent PT-141 nausea?
In a phase 4 single-dose study of 228 healthy women, 8 mg of oral ondansetron given 30 minutes before a 1.75 mg dose did not significantly reduce nausea. The label says pretreatment with oral ondansetron is not recommended [1].
Is MOTS-c FDA-approved?
No. It is not an FDA-approved drug or a component of one. FDA staff recommended against adding it to the compounding bulks list in July 2026, an advisory committee voted the other way in a non-binding vote, and HHS's October 2026 enforcement-discretion policy for it is a draft [2][14][11].
Does PT-141 cause permanent skin darkening?
Focal hyperpigmentation was reported in 1% of women given up to 8 doses a month in the phase 3 trials, versus none on placebo. Resolution was not confirmed in all patients after stopping, and people with dark skin were more likely to develop it [1].
Does the Vyleesi label say anything about MOTS-c?
No. The drug-interaction section names one product to avoid, oral naltrexone, and warns that Vyleesi may slow gastric emptying and reduce absorption of oral medicines such as antibiotics. MOTS-c is not mentioned [1].
Show all 17 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
  2. U.S. Food and Drug Administration.
  3. U.S. Food and Drug Administration.
  4. World Anti-Doping Agency.
  5. World Anti-Doping Agency.
  6. Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54.
  7. Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol. 2019;134(5):899-908.
  8. Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol. 2019;134(5):909-917.
  9. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  10. Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470.
  11. Official web page.
  12. U.S. Food and Drug Administration.
  13. Official web page.
  14. U.S. Food and Drug Administration.
  15. U.S. Food and Drug Administration.
  16. Reddit participants. The libido peptide explained: what PT-141 actually does for sexual desire (r/NTNPerformance). Accessed 2026-11-10.
  17. Reddit participants. PT-141 deep dive: the libido peptide that works on your brain, not your blood flow (r/NTNPerformance). Accessed 2026-11-10.
Evidence overview for PT-141 (Bremelanotide) vs MOTS-c Side-Effect Profile: Head-to-Head Comparison